Key result
ePWV >10 m/s linked to ~79% higher cardiovascular mortality in middle-aged men.
Why the study?
The predictive capacity of estimated pulse wave velocity (ePWV) for cardiovascular disease outcomes has not been tested broadly in the general population.
Does elevated estimated pulse wave velocity predict cardiovascular mortality, sudden cardiac death, and atrial fibrillation in middle-aged men?
Cohort (n=2,666)
Does elevated estimated pulse wave velocity predict cardiovascular mortality, sudden cardiac death, and atrial fibrillation in middle-aged men?
Answers are grounded in this paper and cite their sources.
Elevated estimated pulse wave velocity is independently associated with increased risk of cardiovascular mortality, sudden cardiac death, and atrial fibrillation in men, though it does not improve risk discrimination when added to standard clinical risk scores.
Carotid-femoral pulse wave velocity (cfPWV) by direct measurement with tonometry is the gold standard means for assessing aortic stiffness and is associated with adverse cardiovascular disease (CVD) outcomes.1 Equations using age and mean blood pressure (MBP) may be useful to estimate pulse wave velocity (ePWV)2 and have been shown to predict all-cause and CVD mortality in individuals with hypertension,3 but its predictive capacity for CVD outcomes has yet to be tested more broadly in the general population. The purpose of this study was to evaluate whether ePWV would be associated with CVD outcomes and mortality. This prospective study was based on the general population sample of 2666 middle-aged Caucasian men (aged (mean ± standard deviation) 53.1 ± 5.1, range 42–61 years) in the Kuopio Ischemic Heart Disease cohort study. ePWV was calculated from an equation based on age and MBP.2,3 Levels of ePWV were categorized according to quartiles (<8.5 (the lowest), 8.5–9.2, 9.2–10.0, and >10.0 m/s (the highest)).2,4 Cardiovascular outcomes were operationally defined as cardiovascular mortality (CVM), sudden cardiac death (SCD), and atrial fibrillation (AF). All-cause mortality (ACM) was also assessed. We used Cox proportional hazard adjusted models to determine the hazard ratios (HRs) and 95% confidence intervals (CIs) of ePWV for outcomes. To further evaluated whether ePWV would be associated with an improvement in the prediction of CVM risk using the Systematic Coronary Risk Evaluation (SCORE) algorithm (comprising age, sex, smoking status, systolic blood pressure (SBP), total cholesterol, and high-density lipoprotein cholesterol (HDL-C)) and the Framingham CVD Risk Score (FRS) (comprising age, sex, smoking status, SBP, total cholesterol, HDL-C, and diabetes status), we calculated measures of discrimination (using Harrell’s C-index and difference in –2 log likelihood) and reclassification (using net-reclassification-index (NRI) and integrated-discrimination-improvement (IDI)).5 During a median 25-year follow-up (interquartile ranges: 18–27 years), 1274 ACM, 594 CVM, 255 SCD, and 511 AF events occurred, respectively. Cumulative hazard curves demonstrated lower survival among males of ePWV value >10.0 m/s compared to those of ePWV value <10.0 m/s (P < 0.001 for log-rank test; Figure 1). The cumulative hazard curves for all-cause mortality and cardiovascular mortality by ePWV value >10.0 m/s. After adjusting for CVD risk factors (Table 1), the highest levels of ePWV were significantly associated with an increased risk for ACM (HR 1.39, 95% CI: 1.11–1.73), CVM (HR 1.79, 95% CI, 1.27–2.52), SCD (HR 1.86, 95% CI, 1.11–3.11), and AF (HR 1.46, 95% CI, 1.03–2.06), as compared with the lowest level of ePWV (reference). On addition of ePWV to SCORE, there was no significant increase in the C-index: –0.0001 (95% CI: –0.0012, 0.0010; p = 0.82) and no significant improvement in the –2 log likelihood of the risk score with and without inclusion of ePWV (p for comparison = 0.48). There was no significant improvement in the classification of participants into predicted 10-year CVM risk categories (NRI: 0.26%, –2.88, 3.40%; p = 0.87). The IDI was –0.0001 (–0.0007, 0.0004; p = 0.62). For the FRS, the C-index change was 0.0002 (95% CI: −0.0012, 0.0016; p = 0.77); −2 log likelihood p-value for comparison = 0.31; NRI = 1.03% (−1.57, 3.63%; p = 0.44); and IDI = −0.0001 (−0.0010, 0.0007; p = 0.78). The hazard ratios and 95% confidence intervals for all-cause mortality, cardiovascular mortality, sudden cardiac death, and atrial fibrillation by ePWV quartiles (n = 2666). Adjusted for age, body mass index, smoking, diabetes, anti-hypertensive medication, total cholesterol, HDL-C, glucose, C-reactive protein, CVD history, alcohol intake, maximal oxygen uptake, and family history of CVD. ePWV: estimated pulse wave velocity. The hazard ratios and 95% confidence intervals for all-cause mortality, cardiovascular mortality, sudden cardiac death, and atrial fibrillation by ePWV quartiles (n = 2666). Adjusted for age, body mass index, smoking, diabetes, anti-hypertensive medication, total cholesterol, HDL-C, glucose, C-reactive protein, CVD history, alcohol intake, maximal oxygen uptake, and family history of CVD. ePWV: estimated pulse wave velocity. These findings demonstrate that ePWV is related to CVD outcomes and mortality, independent of traditional CVD risk factors, in the general population. Individuals having an ePWV value >10.0 m/s4 were 79% more likely to die from CVD, 86% more likely to die from SCD, and 46% more likely to suffer from AF, compared to those with lower ePWV (<8.5 m/s). Our findings support the importance of elevated arterial stiffness as independently associated with AF risk6 and add to the novel observation that elevated levels of arterial stiffness may also be associated with SCD risk. However, the addition of ePWV to contemporary CVD risk scores such as SCORE and the FRS did not improve discrimination of CVD mortality risk. A limitation of this study is that the cohort examined comprised exclusively men. Additional research examining the role of ePWV as a predictor of CVD events in women is warranted. These findings demonstrate a potential role of arterial stiffness in identifying patients at high risk for adverse cardiovascular outcomes, but further evaluation is warranted in differing populations (general population vs hypertensive) and racial/ethnic backgrounds. Finally, it should be evaluated whether ePWV (like cfPWV) is similarly and favorably modulated by different lifestyle and rehabilitation modalities such as exercise and sauna bathing.7 Sae Young Jae and Kevin S Heffernan contributed to the concept and design. All authors contributed to the acquisition, analysis, or interpretation of data. The drafting of the manuscript was conducted by Sae Young Jae, Kevin S Heffernan, and Setor K Kunutsor. All authors contributed to the critical revision of the manuscript for important intellectual context. Statistical analysis was carried out by Sae Young Jae and Setor K Kunutsor. Jari A Laukkanen supervised the findings of this work. We thank the staff of the Kuopio Research Institute of Exercise Medicine and the Research Institute of Public Health, and University of Eastern Finland, Kuopio, Finland, for data collection in the study. The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The author(s) received no financial support for the research, authorship, and/or publication of this article.
No takes yet. Share an insight, caveat, or question.
Jae et al. (2020) conducted a cohort in General population (n=2,666). Estimated pulse wave velocity (ePWV) >10.0 m/s vs. ePWV <8.5 m/s was evaluated on Cardiovascular mortality (HR 1.79, 95% CI 1.27-2.52). Estimated pulse wave velocity >10.0 m/s was associated with an increased risk of cardiovascular mortality compared to <8.5 m/s in middle-aged men.
Synapse has enriched 10 related papers. Consider them for comparative context: